The United Kingdom and the United States have agreed to a key trade agreement that will guarantee no levies on UK drug exports entering the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to increase spending on drugs through the NHS. This pledge guarantees that duties on these vital products will remain at nothing for a period of 36 months.
This agreement comes after earlier warnings to hike tariffs on branded pharmaceutical imports, with potential rates discussed reaching one hundred percent.
"This agreement between the United Kingdom reinforces the worldwide climate for innovative medicines and establishes long-overdue fairness to American-British medicine commerce," an announcement noted.
Economic Significance
Drugs represent one of the Britain's biggest goods shipped to the United States, which is by far the primary destination for large companies like GSK and AstraZeneca.
Statistics indicate that in the year to the end of the third quarter, the UK shipped drugs valued at over eleven billion pounds to the US. This amount represented a significant portion of total UK exports in that period.
"This agreement secures jobs, stimulates investment and paves the way for the UK to become a international leader for medical research," the Business and Trade Secretary stated.
Key NHS Changes
The agreement involves several key pledges from the UK:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it deems new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to increase overall health service expenditure on treatments from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The amount drug companies must pay back to the NHS to control costs will be restricted at 15%. Last year, rebates topped twenty percent.
Recent Tensions
The deal follows a ongoing dispute between the pharmaceutical industry and the British authorities over spending levels and approval rates.
This friction were heightened by assertions that American customers were charged a premium for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been paused or cancelled, while substantial investments have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS had to increase expenditure on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its total funding over the past decade.
